secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001664710-24-000050
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros receives positive FDA feedback on KER-050 MDS program; Phase 3 design aligned
--------------------------------------------------------------------------------

- FDA feedback resulted in general alignment on design and endpoints for proposed pivotal Phase 3 trial of KER-050 (elritercept) in MDS.
- Company to host corporate update conference call and webcast on Monday, June 17, 2024 at 8:00 a.m. ET.
- Expects to complete enrollment of Phase 2 TROPOS trial evaluating KER-012 (cibotercept) in PAH in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000050/0001664710-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000050/kros-20240604.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer